Hyperlipidemia management is key to overall cardiovascular risk reduction. Validated risk calculators, including the updated PREVENT (Predicting Risk of Cardiovascular Disease Events) equation and Pooled Cohort Equations, should be used to guide lipid-lowering therapy in adults without known atherosclerotic cardiovascular disease (ASCVD). Lipid-lowering medications have shown benefit for primary and secondary prevention of ASCVD, supported by guidelines from the American College of Cardiology/American Heart Association, US Department of Veterans Affairs/US Department of Defense, and the National Institute for Health and Care Excellence. Statins remain first-line agents for primary and secondary prevention, with consistent evidence demonstrating reductions in major adverse cardiovascular events, myocardial infarction, stroke, and all-cause mortality. Statin therapy is recommended for primary prevention in adults 40 to 75 years of age with diabetes, chronic kidney disease stage 3 or higher, or HIV; in patients with low-density lipoprotein cholesterol levels of 190 mg/dL or greater; and in those with elevated 10-year ASCVD risk. Current American College of Cardiology/American Heart Association guidelines expand the recommendation to 30 to 79 years of age. Nonstatin therapies should be considered in patients who cannot tolerate statins or do not achieve adequate low-density lipoprotein cholesterol reduction. Adjunctive therapies may be appropriate for secondary prevention in certain patients. Older adults, younger adults with elevated lifetime risk, and patients of childbearing potential require special considerations. Lipid-lowering therapy should be individualized based on risk assessment, guideline thresholds, and shared decision-making.
RISK CALCULATORS
Management of hyperlipidemia is critical for overall cardiac risk reduction. Risk calculation with validated atherosclerotic cardiovascular disease (ASCVD) tools helps inform lifestyle counseling and treatment decisions. These calculators use patient characteristics to estimate the absolute risk of an ASCVD event and are intended for those without known ASCVD or evidence of subclinical disease (Table 11–5). The 2026 American College of Cardiology/American Heart Association (ACC/AHA) and 2025 US Department of Veterans Affairs/US Department of Defense (VA/DoD) dyslipidemia guidelines and the 2025 ACC/AHA hypertension guidelines recommend assessing ASCVD risk using the newer PREVENT (Predicting Risk of Cardiovascular Disease Events) equation (https://professional.heart.org/en/guidelines-and-statements/prevent-risk-calculator/prevent-calculator).4,6,7
The PREVENT equation calculates 10- and 30-year absolute risk for cardiovascular disease (CVD), ASCVD, and heart failure in adults 30 to 79 years of age. National Institute for Health and Care Excellence guidelines recommend risk assessment with the QRISK3 (QResearch Cardiovascular Risk Algorithm) tool.8 Previously, 2018 ACC/AHA and 2022 US Preventive Services Task Force (USPSTF) guidelines recommended using the Pooled Cohort Equations to assess ASCVD risk.1,9
Notable changes in the PREVENT equation include factors such as removal of race as a category, addition of estimated glomerular filtration rate, and optional variables (eg, zip code to incorporate social drivers of health).2–4,7 Retrospective analysis of National Health and Nutrition Examination Survey data comparing the PREVENT equation with the Pooled Cohort Equations suggests that 81% of treatment recommendations would be similar.5 However, the PREVENT equation identified 18.8% fewer people at increased risk in this study.5 When a treatment recommendation was altered, 75% of patients receiving moderate-intensity therapy were switched to no treatment, and 93% of patients receiving high-intensity therapy changed to moderate-intensity treatment.5 In general, the Pooled Cohort Equations calculator trends toward overestimation of ASCVD risk in the overall population, but the PREVENT equation may underestimate risk in patients not already taking statin therapy.5,10
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
